41060-15-5
41060-15-5 結(jié)構(gòu)式
基本信息
新補(bǔ)骨脂異黃酮, >99%
新補(bǔ)骨脂異黃酮, 來源于補(bǔ)骨脂
新補(bǔ)骨脂異黃酮NEOBAVAISOFLAVONE
NEOBAVAISOFLAVONE 新補(bǔ)骨脂異黃酮
7-羥基-3-(4-羥基-3-(3-甲基丁-2-烯-1-基)苯基)-4H-苯并吡喃-4-酮
7-羥基-3-[4-羥基-3-(3-甲基-2-丁烯-1-基)苯基]-4H-1-苯并吡喃-4-酮
Neobavaisoflavone, >99%
4',7-Dihydroxy-3'-(3-methyl-2-butenyl)isoflavone
Neobavaisoflavone, 98%, from Psoralea corylifolia L.
7-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one
7-Hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)phenyl)-4H-chromen-4-one
7-Hydroxy-3-(4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl)-4H-chromen-4-one
7-Hydroxy-3-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 7-hydroxy-3-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | N1122 | 新補(bǔ)骨脂異黃酮 Neobavaisoflavone | 41060-15-5 | 5mg | 190元 |
| 2024/11/08 | N1122 | 新補(bǔ)骨脂異黃酮 Neobavaisoflavone | 41060-15-5 | 25mg | 560元 |
常見問題列表
DNA polymerase
Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED
50
=25 μM) and cytokine (ED
50
s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages.
Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED
50
of 19.94 μM in activated RAW264.7 cells.
Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells.
Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner.
Neobavaisoflavone (2-8 μM; 7 d) inhibits RANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.
Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.
| Animal Model: | C57BL/6 female mice (8 weeksd; 20-25 g) were removed bilateral ovaries |
| Dosage: | 30 mg/kg |
| Administration: | I.p. for 6 weeks |
| Result: | Attenuated bone loss by inhibiting osteoclast activation and promoting osteogenesis in ovariectomized mice. |